Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth, defying widespread healthcare sector pessimism. The company achieved 14% YoY revenue growth and 18.6% EBITDA growth, far surpassing expectations, and increased guidance for the year. Management accelerated opportunistic share buybacks, returning $908 million to shareholders in the first half of 2025, demonstrating exceptional capital allocation.
After reaching an important support level, Medpace Holdings, Inc. (MEDP) could be a good stock pick from a technical perspective. MEDP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants August James Troendle - Chairman & CEO Jesse J. Geiger - President Kevin M.
Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase
If gains hold, that'd be the stock's largest single-day increase on record.
Medpace (MEDP) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to earnings of $2.75 per share a year ago.
Medpace (MEDP) reached $319.16 at the closing of the latest trading day, reflecting a +1.38% change compared to its last close.
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Medpace (MEDP) stood at $328.24, denoting a +2.27% move from the preceding trading day.
Medpace (MEDP) closed the most recent trading day at $326.03, moving +1.55% from the previous trading session.
Medpace (MEDP) closed the most recent trading day at $306.8, moving 1.39% from the previous trading session.